drugset / Trial / NCT02861261

A Study on the Efficacy and Gut Microbiota of Berberine and Probiotics in Patients With Newly Diagnosed Type 2 Diabetes

NCT02861261

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to conduct a multicenter randomized, double-blind, placebo-controlled clinical trial, evaluating the effects and change of gut microbiota after berberine and/or probiotics administration in patients with newly diagnosed type 2 diabetes

Timeline

Start
2016-08-18
Primary completion
2017-12
Completion
2019-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Berberine Traditional medicine (herbal / TCM) 0.6 g Oral
Subject ProMetS Other / unclassified 4 g Oral